Kymera Therapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Kymera TherapeuticsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -32.5% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 1.8% pro Jahr.

Wichtige Informationen

-29.9%

Wachstumsrate der Gewinne

64.7%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	5.4%
Eigenkapitalrendite	-23.0%
Netto-Marge	-178.3%
Letzte Ertragsaktualisierung	30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Aug 11

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up

Jul 14

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Jun 12

We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

May 03

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

Mar 21

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Feb 25

Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Feb 17

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

Dec 29

We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Nov 06

Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Aug 31

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Aug 04

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

May 21

We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Apr 16

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Dec 28

Kymera KT-333 gets FDA orphan drug status for blood cancer subtype

Sep 15

Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces

Aug 15

Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M

Aug 09

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Jul 04

Aufschlüsselung der Einnahmen und Ausgaben

Wie Kymera Therapeutics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGM:KYMR Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
30 Jun 24	89	-158	60
31 Mar 24	79	-155	57
31 Dec 23	79	-147	55
30 Sep 23	47	-167	52
30 Jun 23	52	-158	49
31 Mar 23	47	-159	46
31 Dec 22	47	-155	44
30 Sep 22	46	-154	44
30 Jun 22	57	-139	44
31 Mar 22	64	-124	41
31 Dec 21	73	-100	36
30 Sep 21	70	-79	30
30 Jun 21	65	-58	26
31 Mar 21	49	-48	22
31 Dec 20	34	-55	18
30 Sep 20	23	-53	16
30 Jun 20	9	-57	10
31 Mar 20	6	-52	9
31 Dec 19	3	-41	8

Qualität der Erträge: KYMR ist derzeit unrentabel.

Wachsende Gewinnspanne: KYMR ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: KYMR ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 32.5% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von KYMR verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: KYMR ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (-14.4%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: KYMR hat eine negative Eigenkapitalrendite (-21.74%), da es derzeit unrentabel ist.

Kymera Therapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Kymera Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Kymera Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Kymera Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Recent updates

Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Kymera Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up

Kymera Therapeutics, Inc. Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of Stat3 Degrader Kt-333 At Eha Annual Meeting

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Kymera Therapeutics, Inc. Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of Stat3 Degrader KT-333 At EHA Annual Meeting

Consensus EPS estimates upgraded to US$2.90 loss, revenue downgraded

We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

Kymera Therapeutics, Inc. Provides Business Highlights and Updates on Its Pipeline of Protein Degraders

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Kymera Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Price target increased by 7.0% to US$51.07

Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting

New minor risk - Insider selling

Consensus revenue estimates increase by 45%

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Kymera Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Chief Medical Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Price target increased by 8.3% to US$43.00

Price target increased by 7.3% to US$42.77

New minor risk - Shareholder dilution

Kymera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $274.999133 million.

Kymera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $274.999133 million.

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

Kymera Therapeutics, Inc. Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656)p

Kymera Therapeutics, Inc. Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-In-Class IRAK4 Degrader, in Nature Medicine

Consensus revenue estimates decrease by 18%, EPS upgraded

Consensus revenue estimates decrease by 12%, EPS upgraded

We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Kymera Therapeutics, Inc. to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting

Price target decreased by 16% to US$47.47

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Kymera Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656)

Kymera Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Kymera Therapeutics, Inc. Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

New major risk - Revenue and earnings growth

Kymera Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma

Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Consensus revenue estimates increase by 19%

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kymera Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Kymera Therapeutics, Inc.(NasdaqGM:KYMR) dropped from Russell Small Cap Comp Value Index

Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413

Kymera Therapeutics, Inc. Presents Data Demonstrating Superior Efficacy of Kt-253, A Potent and Selective Heterobifunctional Mdm2 Degrader

Kymera Appoints Jeremy Chadwick as Chief Operating Officer

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

Kymera Therapeutics, Inc. Presents Clinical Data from the Phase 1 Trial of Irak4 Degrader, KT-474 (Sar444656), At the European Academy of Dermatology and Venereology Symposium

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Consensus revenue estimates fall by 13%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Kymera Therapeutics, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Kymera Therapeutics, Inc. Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Kymera Therapeutics, Inc. Announces Positive Clinical Results from the Patient Cohort Portion of Its KT-474 (IRAK4) Phase 1 Clinical Trial